Economic Evaluation of Varicella Vaccination Programmes: A Review of the Literature

[1]  F. Henry,et al.  Cost effectiveness. , 1980, The Ohio State medical journal.

[2]  M. Postma,et al.  Do costs of varicella justify routine infant vaccination? , 2004, The European Journal of Health Economics, formerly: HEPAC.

[3]  P Wutzler,et al.  The cost-effectiveness of routine childhood varicella vaccination in Germany. , 2003, Vaccine.

[4]  E. Doorslaer,et al.  Economic Evaluations of Varicella Vaccination Programmes , 2003, PharmacoEconomics.

[5]  J. Seward,et al.  Hospitalizations for varicella in the United States, 1988 to 1999 , 2002, The Pediatric infectious disease journal.

[6]  A. Hall,et al.  Contacts with varicella or with children and protection against herpes zoster in adults: a case-control study , 2002, The Lancet.

[7]  P. Wutzler,et al.  Can varicella be eliminated by vaccination? Potential clinical and economic effects of universal childhood varicella immunisation in Germany , 2002, Medical Microbiology and Immunology.

[8]  W. Edmunds,et al.  Exposure to varicella boosts immunity to herpes-zoster: implications for mass vaccination against chickenpox. , 2002, Vaccine.

[9]  J. Caro,et al.  Instituting a routine varicella vaccination program in Canada: an economic evaluation , 2002, The Pediatric infectious disease journal.

[10]  M. Wharton,et al.  Varicella Vaccine and Shingles—Reply , 2002 .

[11]  W. Edmunds,et al.  Varicella vaccine and shingles. , 2002, JAMA.

[12]  L. Mascola,et al.  Varicella disease after introduction of varicella vaccine in the United States, 1995-2000. , 2002, JAMA.

[13]  W. Edmunds,et al.  The cost-effectiveness of varicella vaccination in Canada. , 2002, Vaccine.

[14]  H. Glick,et al.  Economic Evaluation of Vaccination Programmes , 2002, PharmacoEconomics.

[15]  P. Beutels.  Economic evaluations of hepatitis B immunization: a global review of recent studies (1994-2000). , 2001, Health economics.

[16]  E. Shapiro,et al.  The effectiveness of the varicella vaccine in clinical practice. , 2001, The New England journal of medicine.

[17]  W. Edmunds,et al.  Modelling the impact of immunization on the epidemiology of varicella zoster virus , 2000, Epidemiology and Infection.

[18]  W. P. Stephenson,et al.  The postmarketing safety profile of varicella vaccine. , 2000, Vaccine.

[19]  G. Moens,et al.  Occupational risk of infection by varicella zoster virus in Belgian healthcare workers: a seroprevalence study , 2000, Occupational and environmental medicine.

[20]  M. Wharton,et al.  Varicella mortality: trends before vaccine licensure in the United States, 1970-1994. , 2000, The Journal of infectious diseases.

[21]  W. Edmunds,et al.  Analysis of varicella vaccine breakthrough rates: implications for the effectiveness of immunisation programmes. , 2000, Vaccine.

[22]  D. Klinman,et al.  Varicella vaccination: Evidence for frequent reactivation of the vaccine strain in healthy children , 2000, Nature Medicine.

[23]  D J Nokes,et al.  Evaluating the cost-effectiveness of vaccination programmes: a dynamic perspective. , 1999, Statistics in medicine.

[24]  E. Walter,et al.  Postlicensure study of varicella vaccine effectiveness in a day-care setting. , 1999, The Pediatric infectious disease journal.

[25]  M. Johannesson,et al.  Inconsistencies in the "Societal Perspective" on Costs of the Panel on Cost-Effectiveness in Health and Medicine , 1999, Medical decision making : an international journal of the Society for Medical Decision Making.

[26]  S. Straus,et al.  Epinephrine and outcome after cardiac arrest. , 1999, Annals of internal medicine.

[27]  J. Latour,et al.  A cost benefit analysis of routine varicella vaccination in Spain. , 1999, Vaccine.

[28]  L. Coudeville,et al.  The value of varicella vaccination in healthy children: cost-benefit analysis of the situation in France. , 1999, Vaccine.

[29]  Ben A. van Hout,et al.  Discounting costs and effects: a reconsideration. , 1998 .

[30]  A. Mushlin,et al.  Cost‐Effectiveness of Routine Antenatal Varicella Screening , 1998, Obstetrics and gynecology.

[31]  P. Strebel,et al.  Postlicensure effectiveness of varicella vaccine during an outbreak in a child care center. , 1997, JAMA.

[32]  B. Yawn,et al.  Community impact of childhood varicella infections. , 1997, The Journal of pediatrics.

[33]  M. Koopmanschap,et al.  Productivity costs measurement through quality of life? A response to the recommendation of the Washington Panel. , 1997, Health economics.

[34]  P. Keller,et al.  Measles, mumps, rubella, and varicella combination vaccine: safety and immunogenicity alone and in combination with other vaccines given to children. Measles, Mumps, Rubella, Varicella Vaccine Study Group. , 1997, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[35]  D. Stevenson,et al.  Varicella vaccine in pregnancy , 1996, BMJ.

[36]  M E Halloran,et al.  Epidemiologic effects of varicella vaccination. , 1996, Infectious disease clinics of North America.

[37]  B. Cryan,et al.  Susceptibility to varicella zoster virus infection in health care workers. , 1996, Occupational medicine.

[38]  D. Rouse,et al.  Management of the Presumed Susceptible Varicella (Chickenpox)‐Exposed Gravida: A Cost‐Effectiveness/Cost‐Benefit Analysis , 1996, Obstetrics and gynecology.

[39]  V Demicheli,et al.  An exercise on the feasibility of carrying out secondary economic analyses. , 1996, Health economics.

[40]  M A Koopmanschap,et al.  The friction cost method for measuring indirect costs of disease. , 1995, Journal of health economics.

[41]  G. Oster,et al.  Childhood vaccination against chickenpox: an analysis of benefits and costs. , 1994, The Journal of pediatrics.

[42]  M. Halloran,et al.  Cost-effectiveness of a routine varicella vaccination program for US children. , 1994, JAMA.

[43]  G. Mooney,et al.  QALY league tables: handle with care. , 1993, Health economics.

[44]  B. Grenfell,et al.  The epidemiology of varicella–zoster virus infections: the influence of varicella on the prevalence of herpes zoster , 1992, Epidemiology and Infection.

[45]  M. Parsonage,et al.  Discounting and health benefits. , 1992, Health economics.

[46]  P. Robertson,et al.  Determination and importance of varicella immune status of nursing staff in a children's hospital. , 1990, The Journal of hospital infection.

[47]  E. Scolnick,et al.  Live attenuated varicella virus vaccine. Efficacy trial in healthy children. , 1984, The New England journal of medicine.

[48]  E. Keeler,et al.  Discounting of Life-Saving and Other Nonmonetary Effects , 1983 .

[49]  S. Finkler.  The distinction between cost and charges. , 1982, Annals of internal medicine.

[50]  M. Weinstein,et al.  Foundations of cost-effectiveness analysis for health and medical practices. , 1977, The New England journal of medicine.

[51]  Y. Okuno,et al.  Live vaccine used to prevent the spread of varicella in children in hospital. , 1974, Lancet.

[52]  Hope-Simpson Re.  THE NATURE OF HERPES ZOSTER: A LONG-TERM STUDY AND A NEW HYPOTHESIS. , 1965 .